Brentuximab vedotin shows extended survival in Hodgkin lymphoma patients

12/16/2013 | Healio (free registration)

Brentuximab vedotin, an antibody drug conjugate that binds to the protein CD30, showed promising benefits in a midstage trial involving 102 patients with Hodgkin lymphoma who received autologous stem cell transplants. About 10% of the study participants achieved long-term remission, raising the possibility that the drug may be curative for a subset of patients, said the University of Washington's Dr. Ajay Gopal.

View Full Article in:

Healio (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Affairs Specialist
Becton Dickinson
Franklin Lakes, NJ
Customer Service Director
Minneapolis, MN
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Behavioral Health Operations Director
Minneapolis, MN
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID